allocation of deceased donor kidneys phil clayton nsw renal group 14 june 2012

50
Allocation of deceased donor kidneys Phil Clayton NSW Renal Group 14 June 2012

Upload: poppy-lyons

Post on 27-Dec-2015

216 views

Category:

Documents


2 download

TRANSCRIPT

Allocation of deceased donor kidneys

Phil ClaytonNSW Renal Group

14 June 2012

Outline

• Why study kidney allocation?• Equity vs utility• Current Australian model• Previous work in Australia• US allocation research• Allocation simulations

– Current model– A utility-based model

• Future directions

Dialys is patients

Transplants performed

020

0040

0060

0080

0010

000

Cou

nt

1995 2000 2005 2010Year

Australian dialysis patients vs transplants performedDemand vs supply

Equity vs utility trade-off

• Equity– Everyone has opportunity to benefit from

transplantation• Utility

– Get most out of precious resource– Patient survival– Graft survival– QALYs?– Cost effectiveness??

• Whose perspective?– Patient / Donor / System / Society

Current Australian model

Current Australian model

• Major listing criteria:– ESKD on dialysis– 80% likelihood of surviving for at least 5 years after

transplantation• Major allocation criteria:

– Blood group Equity/Utility– Waiting time Equity– HLA match Utility– Highly sensitised Equity/Utility– Childhood Utility

NSW formula

Other states

• VIC – HLA-B, -DR, waiting time• SA – HLA-A, -B, -DR, waiting time• QLD – HLA-A, -B, -DR, waiting time, paediatric

status• WA – HLA-A, -B, -DR; HLA-DR homozygous;

waiting time

ABO rulesDonor Recipient Australia NSW VIC SA QLD WA

A A ✔ ✔ ✔ ✔ ✔ ✔A AB ✔ ✔ ✔ ✔ ✔ ✔AB AB ✔ ✔ ✔ ✔ ✔ ✔B AB ✔ ✔ ✔ ✔ ✔ ✔B B ✔ ✔ ✔ ✔ ✔ ✔O A ✖ ✖ ✖ ✔ ✖ ✖O AB ✖ ✖ ✖ ✔ ✖ ✔O B ✖ ✖ ✖ ✔ ✔ ✔O O ✔ ✔ ✔ ✔ ✔ ✔

ABO rulesDonor Recipient Australia NSW VIC SA QLD WA

A A ✔ ✔ ✔ ✔ ✔ ✔A AB ✔ ✔ ✔ ✔ ✔ ✔AB AB ✔ ✔ ✔ ✔ ✔ ✔B AB ✔ ✔ ✔ ✔ ✔ ✔B B ✔ ✔ ✔ ✔ ✔ ✔O A ✖ ✖ ✖ ✔ ✖ ✖O AB ✖ ✖ ✖ ✔ ✖ ✔O B ✖ ✖ ✖ ✔ ✔ ✔O O ✔ ✔ ✔ ✔ ✔ ✔

0.00

0.25

0.50

0.75

1.00

0 5 10 15Years

012

345

6

HLA mismatch

Australian DD grafts 1995-2009Patient survival

0.00

0.25

0.50

0.75

1.00

0 5 10 15Years

012

345

6

HLA mismatch

Australian DD grafts 1995-2009Death-censored graft survival

0.00

0.25

0.50

0.75

1.00

0 5 10 15Years

0-1920-3940-5960-7980-100

Peak PRA

Australian DD grafts 1995-2009Death-censored graft survival

0.00

0.25

0.50

0.75

1.00

0 5 10 15Years

0-2425-34

35-4445-5455-64

65+

Age

Australian DD grafts 1995-2009Patient survival

0.00

0.25

0.50

0.75

1.00

0 5 10 15Years

0-2425-34

35-4445-5455-64

65+

Donor age

Australian DD grafts 1995-2009Death-censored graft survival

010

020

030

040

0Fr

eque

ncy

-100 -50 0 50

Australian DD grafts 1995-2009Age difference (donor minus recipient age)

Old donorsYoung patients

Young donorsOld patients

More benefit from age matching if higher proportion of older donors

0.00

0.25

0.50

0.75

1.00

0 5 10 15Years

Other

Diabetic nepropathy

Primary disease

Australian DD grafts 1995-2009Patient survival

020

4060

80A

ge (y

ears

)

1990

1991

1992

1993

1994

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

Australia 1990-2010Deceased kidney donor age

020

4060

80A

ge (y

ears

)

1990

1991

1992

1993

1994

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

Australia 1990-2010Deceased kidney donor age

0

10

20

30

40

50

60

%

1995 2000 2005 2010Ye a r

History of smokingHypertension

Diabetes

3- year m oving aver age

Au s tra l i a n d e c e a s e d k id n e y d o n o rs 1 9 9 3 -2 0 1 0

Donor co-morbidities

0

20

40

60

80

100

%

1995 2000 2005 2010

Ye a r

Brain death, standard criteriaBrain death, expanded criteria

Cardiac death

Au s tra l i a 1 9 9 3 -2 0 1 0

Deceased kidney donor profile

US allocation research

• Extensive modelling and simulations• Proposed algorithm:

– Scores for kidney donors and wait-listed patients– Top 20% kidneys -> top 20% recipients– Other 80% kidneys -> recipients aged within 15

years of donor

Allocation simulations

Waiting list

Donor poolAllocation algorithms

Outcomes• Equity of access• Utility

• Patient survival• Graft survival• ? others

Simulation software

NOMS-ANZDATA link

• NOMS– National database of kidney allocation– Since 2000 (Y2K)– Detailed waiting list data since 28 June 2006– Data extract 2001-2010– Demographics, serology, antibodies, crossmatch

results, organ match results– Probabilistic linkage with ANZDATA

Simulation modelling

• Visit to Ann Arbor, Michigan– Great people– Spring snow (new jacket)– Bad coffee

• Simulation software– Developed for US– Adapted for ANZDATA/ANZOD/NOMS data– Australia allocation rules– Validation against actual allocation

02

04

06

08

0A

ge

(y

ea

rs)

Ac tua l Simulated

Age

05

00

1,0

00

1,5

00

Fre

qu

en

cy

Female Male

Sex0

50

01

,00

01

,50

0F

req

ue

nc

y

Wh i te ATSI As ian Other

Race0

20

040

060

080

01,0

00

Fre

qu

en

cy

GN

Analges ic

Po lyc y s tic

Reflux

Hy pertens io

n

Diabete

s

Other

Uncertain

Primary disease

ActualSimulated

01

00

20

03

00

40

0W

ait

ing

tim

e (

mo

nth

s)

Ac tua l Simulated

Waiting time

01

00

20

03

00

40

05

00

Fre

qu

en

cy

0 1 2 3 4 5 6

HLA mismatch0

20

40

60

80

10

0P

ea

k P

RA

Ac tua l Simulated

Peak PRA0

50

01

,00

01

,50

0F

req

ue

nc

y

1 2 3 4 5

Graft number

ActualSimulated

Actual

State Out In Balance

NSW 92 78 14

VIC 55 58 -3

QLD 44 47 -3

SA 34 44 -10

WA 32 30 2

State balance

Simulated

State Out In Balance

NSW 69 62 7

VIC 68 45 23

QLD 34 54 -20

SA 38 47 -9

WA 27 28 -1

Utility-based allocation

• Factors affecting transplant benefit– Age– Sex– Race– Primary disease– Co-morbidities

• Diabetes• Coronary disease• Peripheral vascular disease• Cerebrovascular disease• Chronic lung disease• Smoking history

– Body mass index– Time on RRT– Waiting time– Donor age– Ischaemic time– HLA mismatch– Peak PRA

Median 12.0 years

0.2

5.5

.75

1P

atie

nt s

urvi

val

0 5 10 15Years

Deceased donor transplant

Age 65, male, white, diabetic nephropathy, overweightProjected survival after deceased donor transplant

Median 5.5 years

0.2

5.5

.75

1P

atie

nt s

urvi

val

0 5 10 15Years

Waiting list

Age 65, male, white, diabetic nephropathy, overweightProjected survival on waiting list

Median benefit 6.5 years

0.2

5.5

.75

1P

atie

nt s

urvi

val

0 5 10 15Years

Deceased donor transplant

Waiting list

Age 65, male, white, diabetic nephropathy, overweightProjected benefit from deceased donor transplant

Median benefit 21.0 years

0.2

5.5

.75

1P

atie

nt s

urvi

val

0 5 10 15 20 25 30 35 40Years

Deceased donor transplant

Waiting list

Age 20, male, white, GN, normal weightProjected benefit from deceased donor transplant

Median benefit 17.6 years

0.2

5.5

.75

1P

atie

nt s

urvi

val

0 5 10 15 20 25 30 35 40Years

Deceased donor transplant

Waiting list

Age 30, male, white, GN, normal weightProjected benefit from deceased donor transplant

Median benefit 14.3 years

0.2

5.5

.75

1P

atie

nt s

urvi

val

0 5 10 15 20 25 30 35 40Years

Deceased donor transplant

Waiting list

Age 40, male, white, GN, normal weightProjected benefit from deceased donor transplant

Median benefit 11.2 years

0.2

5.5

.75

1P

atie

nt s

urvi

val

0 5 10 15 20 25 30 35 40Years

Deceased donor transplant

Waiting list

Age 50, male, white, GN, normal weightProjected benefit from deceased donor transplant

Median benefit 8.4 years

0.2

5.5

.75

1P

atie

nt s

urvi

val

0 5 10 15 20 25 30 35 40Years

Deceased donor transplant

Waiting list

Age 60, male, white, GN, normal weightProjected benefit from deceased donor transplant

Median benefit 6.1 years

0.2

5.5

.75

1P

atie

nt s

urvi

val

0 5 10 15 20 25 30 35 40Years

Deceased donor transplant

Waiting list

Age 70, male, white, GN, normal weightProjected benefit from deceased donor transplant

Median benefit 3.9 years

0.2

5.5

.75

1P

atie

nt s

urvi

val

0 5 10 15 20 25 30 35 40Years

Deceased donor transplant

Waiting list

Age 80, male, white, GN, normal weightProjected benefit from deceased donor transplant

Utility-based allocation

• Factors affecting transplant benefit– Age– Sex– Race– Primary disease– Co-morbidities

• Diabetes• Coronary disease• Peripheral vascular disease• Cerebrovascular disease• Chronic lung disease• Smoking history

– Body mass index– Time on RRT– Waiting time– Donor age– Ischaemic time– HLA mismatch– Peak PRA

Benefit = 26 – (age/4) - (donor age/20) - (HLA mismatch/3) - (peak PRA/20)

02

04

06

08

0A

ge

(y

ea

rs)

Current Uti l i ty -bas ed

Age

05

00

1,0

00

1,5

00

Fre

qu

en

cy

Female Male

Sex0

50

01

,00

01

,50

0F

req

ue

nc

y

Wh i te ATSI As ian Other

Race0

20

040

060

080

01,0

00

Fre

qu

en

cy

GN

Analges ic

Po lyc y s tic

Reflux

Hy pertens io

n

Diabete

s

Other

Uncertain

Primary disease

CurrentUtility-based

01

00

20

03

00

40

0W

ait

ing

tim

e (

mo

nth

s)

Current Uti l i ty -bas ed

Waiting time

02

00

40

06

00

Fre

qu

en

cy

0 1 2 3 4 5 6

HLA mismatch0

20

40

60

80

10

0P

ea

k P

RA

Current Uti l i ty -bas ed

Peak PRA0

50

01

,00

01

,50

0F

req

ue

nc

y

1 2 3 4 5

Graft number

CurrentUtility-based

Current

Utility -based

010

2030

40Li

fe e

xpec

tanc

y

0 20 40 60 80Age

Current vs utility-based DD allocationLife expectancy by age

Current

Utility -based

Waiting lis t age dis tribution

010

2030

40Li

fe e

xpec

tanc

y

0 20 40 60 80Age

Current vs utility-based DD allocationLife expectancy by age

Obs erv ed Simulated

Current deceased donor kidney allocat ion system

Ut ilit y-based deceased donor kidney allocat ion system

0

100

200

300

400

Liv

ing

do

no

r tr

an

sp

lan

ts

2002 2004 2006 2008 2010

Ye a r

Au s tra l i a 2 0 0 2 -2 0 1 0

Living donor transplantation rate

Current

State Out In Balance

NSW 69 62 7

VIC 68 45 23

QLD 34 54 -20

SA 38 47 -9

WA 27 28 -1

State balance

Utility-based

State Out In Balance

NSW 282 474 -192

Vic 366 340 26

QLD 286 272 14

SA 250 112 138

WA 141 127 14

Future directions

• More sophisticated allocation models• Sensitivity analyses

– Changes in waiting list– Changes in donor pool

• QALYs• Economic analyses

Acknowledgements• ANZDATA

– Blair Grace– Stephen McDonald– Steve Chadban

• NOMS– Jeremy Chapman– Jenni Wright– Paul Slater

• Arbor Research Collaborative for Health– Keith McCullough– Bob Merion– Alan Leichtman

• Australian and New Zealand patients and staff for their cooperation and contributions to ANZDATA and ANZOD